REMIfentanil (2 vs. 4 mcg/kg) Facilitated Intubation Without Neuromuscular Blockade Versus Succinylcholine and Rocuronium With Sugammadex for Endotracheal Intubation in Spine Surgery Requiring Motor Evoked Potential Monitoring

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT07835295
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Airway Management
  • Endotracheal Intubation

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Low-Dose Remifentanil — DRUG
    Remifentanil 2 mcg/kg intravenous bolus
  • High-Dose Remifentanil — DRUG
    Remifentanil 4 mcg/kg intravenous bolus
  • Succinylcholine — DRUG
    Succinylcholine 1 mg/kg intravenous bolus
  • Rocuronium — DRUG
    Rocuronium 0.6 mg/kg intravenous bolus
  • Sugammadex — DRUG
    Sugammadex reversal after intubation

Study Details

The purpose of this research is to compare four commonly used anesthesia medication strategies for placing a breathing tube in patients undergoing spine surgery that requires motor evoked potential (MEP) monitoring.

Key Dates

First listed
Sep 22, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Sep 30, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
316 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Low-Dose Remifentanil
    Participants receive remifentanil 2 mcg/kg intravenous bolus after standardized propofol induction.
  • Experimental: High-Dose Remifentanil
    Participants receive remifentanil 4 mcg/kg intravenous bolus after standardized propofol induction.
  • Active Comparator: Succinylcholine Control
    Participants receive succinylcholine 1 mg/kg intravenous bolus after standardized propofol induction.
  • Active Comparator: Rocuronium With Sugammadex
    Participants receive rocuronium 0.6 mg/kg intravenous bolus after standardized propofol induction, followed by sugammadex reversal after intubation according to protocol.

Primary Outcome Measure

Percentage of Participants With Clinically Acceptable Intubating Conditions [ Time Frame: During the first endotracheal intubation attempt after study drug administration, assessed within approximately 10 minutes after induction of anesthesia ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicJacksonvilleFlorida32224-

Find similar trials in Jacksonville, FL

By research site
Mayo Clinic· Jacksonville, FL

Related Studies